insulin aspart vs SAR341402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin aspart · NovoLog
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07652528 (registry estimate)
No aligned efficacy figure on record for this race.
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
Reported efficacy
Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)
Result source: NCT03211858
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin aspart | SAR341402 |
|---|---|---|
| HbA1c, change | -1.2% vs -1.3%vs IGlarNCT0097228319 other results
| -0.4% vs -0.3%vs NovoLog/NovoRapidNCT032118581 other result
|
| Body weight, change (kg) | 2.7 vs 2.2vs Insulin GlargineNCT0488085011 other results
| —Not reported |
| HbA1c below 7% | 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978 | 16.6% vs 14.5%vs NovoLog/NovoRapidNCT032118581 other result
|
| Fasting plasma glucose, change | -1.8 vs -1.6vs Insulin GlargineNCT048808505 other results
| -0.5 vs -0.2vs NovoLog/NovoRapidNCT032118581 other result
|
| 3-point MACE (% with event) | —Not posted · NCT01467323 | —Not reported |
HbA1c, change
- insulin aspart
- -1.2% vs -1.3%vs IGlarNCT00972283
19 other results
- -1.2% vs -1.2% NCT04880850
- -1.5% vs -1.4% NCT02762578
- -1.9% vs -1.7% NCT01513590
- -1.4% vs -1.4% NCT01059812
- -0.7% vs 0.1% NCT01388361
- -1.4% vs -1.2% NCT01272193
- -1.0% vs -1% NCT01045447
- -1.6% vs -1.7% NCT01045707
- -1.3% vs -1.3% NCT01009580
- -1.1% vs -1.1% NCT02648217
- -1.4% vs -1.3% NCT01045707
- -0.9% vs -1.1% NCT00972283
- -1.2% vs -1.3% NCT02453685
- -1.0% vs -1.1% NCT01165684
- -0.5% vs 0% NCT04538352
- 4.1% vs 3.4% NCT01966978
- -0.5% vs -0.5% NCT01194258
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- SAR341402
- -0.4% vs -0.3%vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.3% vs -0.3% NCT03211858
Body weight, change (kg)
- insulin aspart
- 2.7 vs 2.2vs Insulin GlargineNCT04880850
11 other results
- 2.8 vs 2.2 NCT02762578
- 2.8 vs 2 NCT01513590
- -1 vs 0.1 NCT01388361
- 0.7 vs 0.7 NCT01272193
- 1.1 vs 1.4 NCT01059812
- 0.9 vs 0.3 NCT01474538
- -8.6 vs 1.4 NCT04538352
- -0.6 vs 3.1 NCT01966978
- 1.5 vs 1.6 NCT01194258
- 0.3 vs 0.8 NCT00998335
- 0.1 vs -0.1 NCT00842361
- SAR341402
- —Not reported
HbA1c below 7%
- insulin aspart
- 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978
- SAR341402
- 16.6% vs 14.5%vs NovoLog/NovoRapidNCT03211858
1 other result
- 19.6% vs 18.2% NCT03211858
Fasting plasma glucose, change
- insulin aspart
- -1.8 vs -1.6vs Insulin GlargineNCT04880850
5 other results
- -3.0 vs -1.6 NCT02762578
- -4.4 vs -3.0 NCT01513590
- -0.1 vs -1.2 NCT01388361
- -2 vs -4.4 NCT02648217
- 6.4 vs 4.9 NCT00998335
- SAR341402
- -0.5 vs -0.2vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.1 vs -0.3 NCT03211858
3-point MACE (% with event)
- insulin aspart
- —Not posted · NCT01467323
- SAR341402
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin aspart: 4 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin aspart Rows use multiple source trials | SAR341402 |
|---|---|---|
| Dropout rate | 0%once weeklya NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02453685 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.5% NCT04880850 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 15.4%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 12.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 5.1% NCT01513590 · Phase 3 · registry result, not featured evidence 13.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 6.6%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 6.4%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 6.8%OD NCT01272193 · Phase 3 · registry result, not featured evidence 13.1%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 15.5%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 17.7% NCT01045707 · Phase 3 · registry result, not featured evidence 12.1% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence | 12.3% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | —once weeklya NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results— NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02453685 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT04880850 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 1.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 1% NCT01513590 · Phase 3 · registry result, not featured evidence 5.7% NCT01388361 · Phase 3 · registry result, not featured evidence · combination —IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence —IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 0.7%OD NCT01272193 · Phase 3 · registry result, not featured evidence 3.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 4.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 0%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 1.9% NCT01045707 · Phase 3 · registry result, not featured evidence 1.8% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence — NCT00842361 · Phase 2 · registry result, not featured evidence | 2.7% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Serious AEs | 22.5%once weeklya NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 8.4% NCT02453685 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 7.6% NCT04880850 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 5.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 7.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence 11.8% NCT01474538 · Phase 3 · registry result, not featured evidence 6.6% NCT01513590 · Phase 3 · registry result, not featured evidence 4.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 0.7%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 4.3%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 3.4%OD NCT01272193 · Phase 3 · registry result, not featured evidence 8.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.5%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 4.3%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 11.3% NCT01045707 · Phase 3 · registry result, not featured evidence 8.5% NCT01009580 · Phase 3 · registry result, not featured evidence 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence | 12% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | once weeklya pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 22 more resultsgi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.7% headache 7.2% arthralgia 6.6% NCT02453685 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence covid-19 8.6% diarrhoea 5.2% diabetic retinopathy 4.1% NCT04880850 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.4% nasopharyngitis 8.9% headache 6.7% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.9% influenza 9% upper respiratory tract infection 7.5% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% rhinitis allergic 4.2% back pain 3.4% NCT01474538 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.7% NCT01513590 · Phase 3 · registry result, not featured evidence nausea 20.7% diarrhoea 10.3% nasopharyngitis 10.3% NCT01388361 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 9% nasopharyngitis 6% NCT01365507 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.7% nasopharyngitis 7.9% NCT01365507 · Phase 3 · registry result, not featured evidence OD nasopharyngitis 22.4% diabetic retinopathy 5.4% NCT01272193 · Phase 3 · registry result, not featured evidence BID nasopharyngitis 18.3% upper respiratory tract infection 7.5% diabetic retinopathy 6.8% NCT01059812 · Phase 3 · registry result, not featured evidence once daily nasopharyngitis 16.5% upper respiratory tract infection 16.3% headache 9.4% NCT00972283 · Phase 3 · registry result, not featured evidence once daily headache 8.7% nasopharyngitis 7.4% diarrhoea 5.2% NCT01045447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% hypertension 7.5% back pain 6% NCT01045707 · Phase 3 · registry result, not featured evidence nasopharyngitis 11.6% upper respiratory tract infection 7.6% headache 5.8% NCT01009580 · Phase 3 · registry result, not featured evidence uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence nasopharyngitis 9.1% supraventricular extrasystoles 6.1% NCT00842361 · Phase 2 · registry result, not featured evidence | nasopharyngitis 11.3% upper respiratory tract infection 7.3% influenza 5% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin aspart
show 12 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
show 1 more result
+ 42 further endpoints in the CSV export.
SAR341402
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · SAR341402's landscape